ID   OCC-26
AC   CVCL_VX39
SY   Oral Cancer Cell-26
DR   IBRC; C11070
DR   Wikidata; Q98128309
RX   PubMed=29672933;
ST   Source(s): PubMed=29672933
ST   Amelogenin: X
ST   CSF1PO: 11
ST   D13S317: 11,12
ST   D16S539: 9,11
ST   D18S51: 17,18
ST   D19S433: 14
ST   D21S11: 28,30
ST   D2S1338: 20,23
ST   D3S1358: 15,16
ST   D5S818: 11,14
ST   D7S820: 7,11
ST   D8S1179: 11,14
ST   FGA: 20,21
ST   TH01: 6,9
ST   TPOX: 8
ST   vWA: 16,17
DI   NCIt; C4833; Oral cavity squamous cell carcinoma
DI   ORDO; Orphanet_502363; Squamous cell carcinoma of the oral cavity
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   81Y
CA   Finite cell line
DT   Created: 24-05-19; Last updated: 21-03-23; Version: 4
//
RX   PubMed=29672933; DOI=10.1111/jop.12717;
RA   Ganjibakhsh, Meysam
RA   Monshizadeh, Roshanak
RA   Nasimian, Ahmad
RA   Aminishakib, Pouyan
RA   Farzaneh, Parvaneh
RA   Tavakoli Shiraji, Sahar
RA   Gharajei, Ata
RA   Rahrotaban, Sedigheh
RA   Baghaei, Fereshteh
RA   Gohari, Neda Sadat
RT   "Anti-angiogenic efficacy of aflibercept and bevacizumab in primary
RT   oral squamous cell carcinoma cells.";
RL   J. Oral Pathol. Med. 47:575-582(2018).
//